Nehodí se? Vůbec nevadí! U nás můžete do 30 dní vrátit
S dárkovým poukazem nešlápnete vedle. Obdarovaný si za dárkový poukaz může vybrat cokoliv z naší nabídky.
30 dní na vrácení zboží
This succinct resource features the most up-to-date knowledge on myeloproliferative neoplasms, including discoveries in JAK2 and MPL mutations, groundbreaking knowledge of the FIP1L1-PDGFRA mutation, new nomenclature and classification, revised WHO-based diagnostic criteria, novel molecular abnormalities, and therapies. International experts provide an ideal balance of new discoveries in biology and practical therapeutic strategies for these diseases. §The authors detail new understanding of genetic mutations and the impact on both the pathophysiologic and clinical contexts of myeloproliferative neoplasms. Diseases covered include essential thrombocythemia, primary and secondary myelofibrosis, hypereosinophic syndrome, chronic eosinophilic leukemia, and systemic mastocytosis. Attention is given to bone marrow findings, revised classification and WHO-based diagnostic criteria, prognostic factors, and treatment options. The full range of therapies is explored from conventional to investigational and anti-JAK2 small molecule drugs to transplant.